Fort Collins, CO – KromaTiD Inc. announced today that it has entered into a strategic partnership with Empire Genomics of Buffalo, NY, to provide a single, comprehensive set of genomic products and services. Targeted at oncology researchers and testing labs worldwide, this combined portfolio will help clinicians, researchers and biopharmaceutical companies better understand the complex genetics of patients with hematologic malignancies and solid tumors.

KromaTiD President and GM Christopher Tompkins stated “KromaTiD’s directional Genomic Hybridization platform, or dGH, is a complete system for the discovery, detection and diagnosis of complex oncogenic rearrangements to the genome. By combining our dGH technology with Empire Genomics’ portfolio of BAC FISH probes and their suite of molecular testing services, including Sanger and Next-Gen Sequencing, we can now offer our customers a complete set of tools capable of analyzing the simplest SNP to the most complex, heterogeneous fusion gene”.

Through this partnership, KromaTiD will also provide Empire’s certified CLIA testing laboratory with analyte specific reagents for unique oncologic targets, streamlining the path to market for KromaTiD’s oncology pipeline of CLIA-ready Pinpoint FISH™ and dGH-based assay products.

An understanding of genomic structural variation is critical to advancing precision medicine in oncology and improving patient care. The combined capabilities of Empire Genomics and KromaTiD will now provide researchers and clinicians with the most comprehensive suite of genomic services available in the market today.

For more information please visit the KromaTiD website.